DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20173708

Comparing the efficacy of Budesonide and Montelukast in children with asthma: a prospective interventional open label controlled clinical study

Sachin S. Jangam, Anupama Mauskar

Abstract


Background: Bronchial asthma is a chronic inflammatory airway disease and is more prevalent in children. Inhaled corticosteroids (Budesonide) and leukotriene receptor antagonist (Montelukast) are the drugs of choice for asthma in children. The present study was aimed to compare the efficacy of these drugs in childhood asthma at tertiary care center.

Methods: This is a prospective interventional open label controlled clinical study carried out from January 2012 to December 2014. Children recently diagnosed with mild persistent asthma that attended Asthma clinic or admitted in ward of department of paediatrics LTMMC and Hospital, Sion, Mumbai was participated in the study. A total of 70 patients were selected for the study and are categorized into two groups consisting of 35 in each group. Group A patients were given metered dose inhaler (MDI) Budesonide 200 mcg 1 puff twice a day (with MDI spacer and mask for children <5 years and without mask for children >5 years. Group B patients were given Montelukast 4 mg (<5 years) and 5 mg (>5 years) tablet as once a daily in the evening for 1 year. Primary and secondary outcome measures were calculated and analysed.

Results: No significant difference on the basis of age and gender was observed among both groups. The complaints of cough, wheeze and breathlessness, lesser emergency department visits, nebulization and lesser number of systemic steroids (days/year) was significantly lesser in patients of group A (p<0.05) compared to group B. Group A subjects had lesser number of acute exacerbations, required lesser number of systemic steroids courses and the frequency of hospitalization. Statistically significant (p<0.05) difference was observed in episode free days in a year among both groups.

Conclusions: The findings of the study prove that Budesonide had better efficacy over Montelukast in control of asthma. 


Keywords


Asthma, Budesonide, Efficacy, Montelukast

Full Text:

PDF

References


Ducharame FM, Davis GM. Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in management of asthma. J Pediatr. 1998;133:475-85.

Koul PA, Patel D. Indian guidelines for asthma: Adherence is the key. Lung India. 2015;32(1):1-2.

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Available at http://www.ginasthma.org/uploads/users/files/GINA Report 2014.pdf. Accessed on 2015 Mar 15.

Cavkaytar O, Sekerel BE. Baseline management of asthma control. Allergol Immunopathol (Madr). 2014;42:162-8.

Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108(3):48.

Kalister H. Treating children with asthma: A review of drug therapies. West J Med. 2001;174(6):415-20.

National Asthma Guidelines Updated. Available at https://www.nhlbi.nih.gov/news/press-releases/2007/national-asthma-guidelines-updated. Accessed on 2015 March 2016.

Rance KS. Helping patients attain and maintain asthma control: reviewing the role of the nurse practitioner. J Multidiscip Health. 2011;4:299-309.

Szefler SJ, Baker JW, Uryniak T, Goldman M, Silkoff PE. Comparative Study of Budesonide Inhalation Suspension and Montelukast in Young Children With Mild Persistent Asthma. J Allergy Clin Immunol. 2007;120(5):1043-50.

Raghava N, Dubey A, Sharma CM. To study the efficacy of inhaled budesonide vs oral montelukast in control of mild persistant asthma in children between 5-18 years of age. IJSR. 2015;6(2):217-22.

Karaman Ö, Sünneli L, Uzuner N, Islekel H, Turgut CS, Köse S. Evaluation of montelukast in 8 to 14 year old children with mild persistent asthma and compared with inhaled corticosteroids. Allergol Immunopathol. 2004;32:21-7.

Szefler SJ, Carlsson LG, Uryniak T, Baker JW. Budesonide inhalation suspension versus montelukast in children aged 2 to 4 years with mild persistent asthma. J Allergy Clin Immunol. 2013;1(1):58-64.

Biswas G, Saha E, Kumar A, Banerjee P. Comparative efficacy and outcome between metered dose inhaled corticosteroids and oral montelukast in mild persistent childhood asthma. Indian Med Gazette. 2013;63-64.

Vidal C, Fernández-Ovide E, Piñeiro J, Nuñez R, González-Quintela A. Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction. Annals Allergy Asthma Immunol. 2001;86(6):655-8.